+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biosimilars Market by Product Type, Therapeutic Area, Administration Route, End User - Global Forecast to 2030- Product Image
Biosimilars Market by Product Type, Therapeutic Area, Administration Route, End User - Global Forecast to 2030- Product Image
Sale

Biosimilars Market by Product Type, Therapeutic Area, Administration Route, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083156
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biosimilars Market grew from USD 49.91 billion in 2024 to USD 61.84 billion in 2025. It is expected to continue growing at a CAGR of 23.47%, reaching USD 176.90 billion by 2030.

Introduction to the Evolving Biosimilars Market

Over the past decade, biosimilars have emerged as cost-effective alternatives to originator biologics, creating opportunities to address growing healthcare budgets and expand patient access to life-changing therapies. Stakeholders across the value chain are adapting to evolving regulatory frameworks, embracing novel development pathways and forging partnerships that accelerate market entry. As the competitive landscape intensifies, manufacturers and payers alike are seeking deeper insights to navigate reimbursement challenges, pricing pressures and supply chain complexities.

This executive summary distills the key factors shaping the biosimilars arena, identifying transformative trends, assessing regulatory and trade policy impacts, and unpacking the granular dynamics across product categories, therapeutic areas, administration routes and end-user channels. Readers will gain perspective on regional adoption patterns, benchmark leading companies and discover actionable recommendations designed to optimize market positioning.

By building on a robust methodology that incorporates primary interviews, secondary intelligence and rigorous data validation, this document offers a credible roadmap for decision-makers in industry, policy and finance. The subsequent sections reveal how emerging shifts, such as tariff changes slated for 2025, intersect with segmentation and regional nuances to define the trajectory of biosimilars. Concluding insights will outline strategic imperatives and invite collaboration to harness sustained growth.

Pivotal Shifts Reshaping the Biosimilars Sphere

Regulatory harmonization has laid the groundwork for biosimilar approvals across major markets, with agencies streamlining comparability requirements and embracing real-world evidence to support interchangeability. At the same time, advances in analytical techniques and process engineering are reducing development timelines and production costs, enabling manufacturers to launch competitive products without compromising quality standards.

Concurrently, digital manufacturing platforms and automation are enhancing batch consistency and laying the foundation for decentralized production models. Cloud-based analytics and artificial intelligence are informing strategic decision making, from target selection to post-market surveillance. These technological enablers are complemented by patent expirations on blockbuster biologics, which have prompted a surge of filings and fostered a more diversified competitive landscape.

Meanwhile, payers are shifting toward value-based care frameworks that reward demonstrated clinical and economic benefits, prompting biosimilar developers to strengthen real-world data collection and engage more closely with health systems. Patient-centric initiatives, such as digital support programs and adherence tools, are becoming integral to market acceptance. Together, these shifts are redefining stakeholder collaborations and setting a new precedent for market entry efficiency.

Assessing the Ripple Effects of US Tariffs in 2025

The announcement of new tariff measures on imported biologics and related components in 2025 is poised to alter global trade flows and cost structures across the biosimilars ecosystem. Although designed to protect domestic manufacturing, these duties may inadvertently elevate production expenses for multinational developers that rely on cross-border supply chains for critical reagents and fill-finish services.

Manufacturers are responding by diversifying sourcing strategies and exploring onshore partnerships to mitigate tariff exposure. Strategic site expansions in low-tariff jurisdictions and dual-sourcing agreements are becoming more prevalent. At the same time, innovators are accelerating technology transfers to local contract manufacturing organizations to maintain cost competitiveness.

This evolving tariff landscape also influences pricing negotiations with payers, as increased landed costs could be passed through or offset by volume-based discounts. Health systems may leverage these changes to renegotiate contracts or prioritize domestic suppliers. Consequently, breaching new tariff thresholds will require a balanced approach that aligns procurement policies with long-term access objectives while preserving the economics of biosimilar adoption.

Dissecting Market Dynamics Through Core Segment Perspectives

When examining product type dynamics, analysis spans erythropoietins, granulocyte colony stimulating factors, growth hormones, insulins, interferons and monoclonal antibodies. Within erythropoietins, the focus falls on darbepoetin alfa and epoetin alfa, while granulocyte colony stimulating factors are detailed through filgrastim and pegfilgrastim. Growth hormone offerings are represented by somatropin, and insulin therapies include both human insulin-with its NPH and regular variants-and insulin analogs subdivided into long acting and rapid acting formulations. Interferons are evaluated across alpha, beta and gamma isoforms, whereas monoclonal antibodies are bifurcated into anti-TNF agents, comprising adalimumab and infliximab biosimilars, and non-TNF agents such as bevacizumab, rituximab and trastuzumab biosimilars.

The therapeutic area lens captures endocrinology, hematology, immunology, infectious diseases and oncology, illuminating how disease-specific prevalence, treatment protocols and reimbursement pathways shape biosimilar uptake. In endocrinology, insulin biosimilars drive cost savings for chronic management, while in oncology, monoclonal antibody biosimilars must overcome complex formulary negotiations and hospital tender processes.

Administration route insight divides the market into intramuscular, intravenous and subcutaneous applications, reflecting clinical preferences and patient convenience. Intravenous formulations are typically administered in hospital settings for acute care, whereas subcutaneous and intramuscular options support self-administration or clinic visits, influencing device design and patient adherence strategies.

End user segmentation distinguishes clinics, homecare and hospitals, each presenting unique procurement channels and stakeholder interactions. Clinics often emphasize cost efficiency and ease of administration for outpatient therapies, homecare providers focus on device usability and remote monitoring, and hospitals prioritize large-volume purchasing agreements and supply reliability for complex infusion protocols.

Unveiling Regional Variations in Biosimilars Adoption

The Americas region has emerged as a leading adopter of biosimilars, driven by robust regulatory support, competitive reimbursement policies and payer incentives that favor cost containment. In the United States, biosimilar interchangeability designations and state-level substitution laws have facilitated rapid uptake in key product categories, particularly in oncology and hematology, while Canadian public plans negotiate national procurement frameworks to secure volume-based rebates.

In Europe, the Middle East and Africa, early biosimilar approvals and established tendering systems have cemented market leadership in monoclonal antibodies and growth hormones. Western European countries leverage tender auctions to drive down prices, while emerging markets in the Middle East and parts of Africa are crafting nascent frameworks to accelerate patient access. Regulatory convergence across the region has reduced duplication of effort, although disparities in health infrastructure and reimbursement maturity continue to influence market penetration rates.

The Asia-Pacific landscape is characterized by dynamic growth, with China, India and South Korea at the forefront of domestic biosimilar development. Government incentives, local manufacturing mandates and public insurance reforms are catalyzing expansion. Meanwhile, regulatory clarity in Australia and Japan underpins steady uptake among hospital systems. As market competition intensifies, region-specific considerations such as import duties, local partnership requirements and tiered insurance coverage will be critical to commercial success.

Spotlight on Leading Biosimilar Developers and Innovators

Several global players are driving innovation and shaping market trajectories through strategic portfolios and alliances. Established generics manufacturers have broadened their biosimilar pipelines to include high-value monoclonal antibodies, leveraging their expertise in large-scale production and regulatory submissions. Meanwhile, biopharmaceutical giants and specialized biotech firms are forging collaborations with contract manufacturing organizations to optimize capacity and accelerate time to market.

Emerging companies are differentiating through targeted indications and niche formulations, focusing on less crowded therapeutic areas or rare disease applications. Partnerships between multinational developers and regional innovators are on the rise, combining local market knowledge with global regulatory experience. These alliances frequently extend beyond development to encompass co-promotion agreements and value-based contracting models with payers.

Investment in next-generation biologics, such as biosuperiors that aim to improve on reference profiles, signals a strategic pivot toward innovation-led growth. As the competitive field matures, the ability to navigate complex patent landscapes, demonstrate robust clinical evidence and deliver comprehensive support services will distinguish market leaders from followers.

Strategic Imperatives for Biosimilar Market Leadership

To capitalize on market potential, industry leaders should prioritize the expansion of advanced manufacturing capabilities, investing in modular and continuous processing platforms that reduce cycle times and enhance supply agility. Cultivating proactive engagement with regulatory authorities can streamline approval pathways and establish early alignment on interchangeability and real-world evidence requirements.

Diversification of supply chains through strategic partnerships and dual-sourcing arrangements will mitigate the impact of trade policy fluctuations and raw material shortages. Equally important is the development of robust payer engagement frameworks that articulate clear value propositions, leverage health economic models and support outcome-based contracts.

Patient support initiatives, including digital adherence tools and telehealth integration, can strengthen market uptake by addressing barriers to therapy initiation and persistence. Collaboration with healthcare professionals on educational programs will foster confidence in biosimilar interchangeability. Finally, data-driven marketing strategies and targeted provider outreach will accelerate adoption and reinforce competitive positioning.

Robust Methodology Underpinning Our Analysis

The analysis underpinning this executive summary combines comprehensive secondary research with in-depth primary interviews. Secondary sources include peer-reviewed journals, regulatory filings, investor presentations and industry white papers, providing a robust foundation of market intelligence. Primary research involved structured conversations with executives, key opinion leaders and procurement specialists to validate trends and uncover emerging needs.

Triangulation of data points ensured consistency and reliability, while segmentation analysis across product types, therapeutic areas, administration routes and end-user channels enabled granular insights. Qualitative inputs were complemented by quantitative metrics, forming a balanced perspective that reflects both strategic imperatives and operational realities.

Rigorous validation processes, including cross-referencing with proprietary databases and expert review panels, were employed to maintain the highest standards of accuracy. This methodology ensures that recommendations are grounded in credible evidence and aligned with current industry dynamics.

Concluding Insights and Future Outlook

The evolving biosimilars market presents both challenges and opportunities, underscored by regulatory progress, technological innovation and shifting trade policies. As tariffs reshape cost structures and regional dynamics continue to diverge, agility and strategic foresight will define the winners of the next phase of growth.

Manufacturers that successfully integrate advanced manufacturing, proactive regulatory engagement and patient-centric support models will secure stronger market positions. Partnerships that balance global expertise with local insights will unlock new channels for adoption, while data-driven value propositions will resonate with payers and providers alike.

By embracing these insights and acting decisively, industry stakeholders can foster sustainable growth, improve patient access and deliver measurable value to healthcare systems worldwide. The path forward requires collaboration, innovation and a steadfast commitment to quality and affordability.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Erythropoietins
      • Darbepoetin Alfa
      • Epoetin Alfa
    • Granulocyte Colony Stimulating Factors
      • Filgrastim
      • Pegfilgrastim
    • Growth Hormones
      • Somatropin
    • Insulins
      • Human Insulin
        • NPH Insulin
        • Regular Insulin
      • Insulin Analogs
        • Long Acting Analog
        • Rapid Acting Analog
    • Interferons
      • Interferon Alpha
      • Interferon Beta
      • Interferon Gamma
    • Monoclonal Antibodies
      • Anti-Tnf Agents
        • Adalimumab Biosimilars
        • Infliximab Biosimilars
      • Non-Tnf Agents
        • Bevacizumab Biosimilars
        • Rituximab Biosimilars
        • Trastuzumab Biosimilars
  • Therapeutic Area
    • Endocrinology
    • Hematology
    • Immunology
    • Infectious Diseases
    • Oncology
  • Administration Route
    • Intramuscular
    • Intravenous
    • Subcutaneous
  • End User
    • Clinics
    • Homecare
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Sandoz International GmbH
  • Pfizer Inc.
  • Amgen Inc.
  • Samsung Bioepis Co., Ltd.
  • Celltrion, Inc.
  • Biocon Limited
  • Viatris Inc.
  • Merck KGaA
  • Fresenius Kabi AG
  • Coherus BioSciences, Inc.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biosimilars Market, by Product Type
8.1. Introduction
8.2. Erythropoietins
8.2.1. Darbepoetin Alfa
8.2.2. Epoetin Alfa
8.3. Granulocyte Colony Stimulating Factors
8.3.1. Filgrastim
8.3.2. Pegfilgrastim
8.4. Growth Hormones
8.4.1. Somatropin
8.5. Insulins
8.5.1. Human Insulin
8.5.1.1. NPH Insulin
8.5.1.2. Regular Insulin
8.5.2. Insulin Analogs
8.5.2.1. Long Acting Analog
8.5.2.2. Rapid Acting Analog
8.6. Interferons
8.6.1. Interferon Alpha
8.6.2. Interferon Beta
8.6.3. Interferon Gamma
8.7. Monoclonal Antibodies
8.7.1. Anti-Tnf Agents
8.7.1.1. Adalimumab Biosimilars
8.7.1.2. Infliximab Biosimilars
8.7.2. Non-Tnf Agents
8.7.2.1. Bevacizumab Biosimilars
8.7.2.2. Rituximab Biosimilars
8.7.2.3. Trastuzumab Biosimilars
9. Biosimilars Market, by Therapeutic Area
9.1. Introduction
9.2. Endocrinology
9.3. Hematology
9.4. Immunology
9.5. Infectious Diseases
9.6. Oncology
10. Biosimilars Market, by Administration Route
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Subcutaneous
11. Biosimilars Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Homecare
11.4. Hospitals
12. Americas Biosimilars Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Biosimilars Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Biosimilars Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Sandoz International GmbH
15.3.2. Pfizer Inc.
15.3.3. Amgen Inc.
15.3.4. Samsung Bioepis Co., Ltd.
15.3.5. Celltrion, Inc.
15.3.6. Biocon Limited
15.3.7. Viatris Inc.
15.3.8. Merck KGaA
15.3.9. Fresenius Kabi AG
15.3.10. Coherus BioSciences, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BIOSIMILARS MARKET MULTI-CURRENCY
FIGURE 2. BIOSIMILARS MARKET MULTI-LANGUAGE
FIGURE 3. BIOSIMILARS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOSIMILARS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY DARBEPOETIN ALFA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY EPOETIN ALFA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY SOMATROPIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY NPH INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY REGULAR INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY LONG ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY RAPID ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON ALPHA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON BETA, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON GAMMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOSIMILARS MARKET SIZE, BY BEVACIZUMAB BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOSIMILARS MARKET SIZE, BY TRASTUZUMAB BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOSIMILARS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOSIMILARS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOSIMILARS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOSIMILARS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOSIMILARS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOSIMILARS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOSIMILARS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 88. CANADA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 89. CANADA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 90. CANADA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 91. CANADA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 92. CANADA BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 93. CANADA BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 94. CANADA BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 95. CANADA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 96. CANADA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 97. CANADA BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 98. CANADA BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 99. CANADA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 100. CANADA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 101. CANADA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. MEXICO BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 103. MEXICO BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 106. MEXICO BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 108. MEXICO BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 109. MEXICO BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 110. MEXICO BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 111. MEXICO BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 113. MEXICO BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 114. MEXICO BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 115. MEXICO BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. GERMANY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. GERMANY BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 175. GERMANY BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 176. GERMANY BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 177. GERMANY BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 178. GERMANY BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 179. GERMANY BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 180. GERMANY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 181. GERMANY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 182. GERMANY BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 183. GERMANY BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 184. GERMANY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 185. GERMANY BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 186. GERMANY BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. FRANCE BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 188. FRANCE BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 189. FRANCE BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 190. FRANCE BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 191. FRANCE BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 192. FRANCE BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 193. FRANCE BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 194. FRANCE BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 195. FRANCE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 196. FRANCE BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 197. FRANCE BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 198. FRANCE BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 199. FRANCE BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 200. FRANCE BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. ITALY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 216. ITALY BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 217. ITALY BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 218. ITALY BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 219. ITALY BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 220. ITALY BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 221. ITALY BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 222. ITALY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 223. ITALY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 224. ITALY BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 225. ITALY BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 226. ITALY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 227. ITALY BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 228. ITALY BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. SPAIN BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 230. SPAIN BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 231. SPAIN BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 232. SPAIN BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 233. SPAIN BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 234. SPAIN BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 235. SPAIN BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 236. SPAIN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 237. SPAIN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 238. SPAIN BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 239. SPAIN BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 240. SPAIN BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 241. SPAIN BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 242. SPAIN BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 258. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 272. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 282. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 284. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. DENMARK BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 286. DENMARK BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 287. DENMARK BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 288. DENMARK BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 289. DENMARK BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 290. DENMARK BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 291. DENMARK BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 292. DENMARK BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 293. DENMARK BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 294. DENMARK BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 295. DENMARK BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 296. DENMARK BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 297. DENMARK BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 298. DENMARK BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. NETHERLANDS BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 300. NETHERLANDS BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 301. NETHERLANDS BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 302. NETHERLANDS BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 303. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 304. NETHERLANDS BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 305. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 306. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 307. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 308. NETHERLANDS BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 309. NETHERLANDS BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 310. NETHERLANDS BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 311. NETHERLANDS BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 312. NETHERLANDS BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 313. QATAR BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 314. QATAR BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 315. QATAR BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 316. QATAR BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 317. QATAR BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 318. QATAR BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 319. QATAR BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 320. QATAR BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 321. QATAR BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 322. QATAR BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 323. QATAR BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 324. QATAR BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 325. QATAR BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 326. QATAR BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 327. FINLAND BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 328. FINLAND BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 329. FINLAND BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 330. FINLAND BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 331. FINLAND BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 332. FINLAND BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 333. FINLAND BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 334. FINLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 335. FINLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 336. FINLAND BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 337. FINLAND BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 338. FINLAND BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 339. FINLAND BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 340. FINLAND BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 341. SWEDEN BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 342. SWEDEN BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 343. SWEDEN BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 344. SWEDEN BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 345. SWEDEN BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 346. SWEDEN BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 347. SWEDEN BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 348. SWEDEN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 349. SWEDEN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 350. SWEDEN BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 351. SWEDEN BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 352. SWEDEN BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 353. SWEDEN BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 354. SWEDEN BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 355. NIGERIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 356. NIGERIA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 357. NIGERIA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 358. NIGERIA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 359. NIGERIA BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 360. NIGERIA BIOSIMILARS MARKET

Companies Mentioned

The companies profiled in this Biosimilars market report include:
  • Sandoz International GmbH
  • Pfizer Inc.
  • Amgen Inc.
  • Samsung Bioepis Co., Ltd.
  • Celltrion, Inc.
  • Biocon Limited
  • Viatris Inc.
  • Merck KGaA
  • Fresenius Kabi AG
  • Coherus BioSciences, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 61.84 Billion
Forecasted Market Value ( USD ) by 2030 $ 176.9 Billion
Compound Annual Growth Rate23.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Biologics & Biosimilars CXO Services Market by Service Type, Therapeutic Area, End User, Deployment Model, Engagement Model - Global Forecast to 2030 - Product Image

Biologics & Biosimilars CXO Services Market by Service Type, Therapeutic Area, End User, Deployment Model, Engagement Model - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Biosimilars - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Biosimilars - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Biosimilars Market - Products, Applications and Regulations - Product Image

Biosimilars Market - Products, Applications and Regulations

  • Report
  • 227 Pages
  • Global
From
Biosimilars Market Industry Trends and Global Forecasts to 2035 - Distribution by Drug Class, Therapeutic Area, Type of Manufacturer, Distribution Channel, Geographical Regions and Leading Players - Product Image

Biosimilars Market Industry Trends and Global Forecasts to 2035 - Distribution by Drug Class, Therapeutic Area, Type of Manufacturer, Distribution Channel, Geographical Regions and Leading Players

  • Report
  • 319 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.